OWLT
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number is N/A due to negative earnings; stock trades at a significant premium to book value despite losses.
- Low Price/Sales ratio (1.32)
- High Price/Book (6.99)
- No P/E due to losses
- Forward P/E (92.63) is excessively high
Growth is present in top-line revenue but not translating to the bottom line.
- Consistent revenue growth (~30%)
- EPS growth is trending sharply negative
- High burn rate implied by operating margins
Long-term performance is catastrophic.
- 1Y return was positive (+18.2%)
- 5Y return is -96.5%
- Recent 6M trend is sharply bearish (-47.8%)
While liquidity is currently stable, the operational health is failing.
- Low Debt/Equity
- Current Ratio > 1.5
- Piotroski F-Score 1/9
- Negative ROA and ROE
Company is in a growth/loss phase; dividends are not a factor.
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OWLT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OWLT
Owlet, Inc.
Primary
|
-96.5% | +11.7% | +18.2% | -47.8% | -3.9% | -5.9% |
|
EMPG
Empro Group Inc.
Peer
|
+299.1% | +299.1% | +299.1% | -2.2% | 0.0% | 0.0% |
|
AGEN
Agenus Inc.
Peer
|
-93.5% | -88.0% | +124.2% | -10.7% | +36.6% | +18.4% |
|
IPHA
Innate Pharma S.A.
Peer
|
-67.1% | -58.3% | -22.5% | -30.5% | -9.0% | +2.9% |
|
NYXH
Nyxoah SA
Peer
|
-85.9% | -65.9% | -43.6% | -44.6% | +7.1% | +11.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OWLT
Owlet, Inc.
|
BEARISH | $139.11M | - | -802.5% | -37.5% | $4.94 | |
|
EMPG
Empro Group Inc.
|
NEUTRAL | $143.05M | 192.89 | 66.3% | 13.7% | $17.36 | Compare |
|
AGEN
Agenus Inc.
|
BEARISH | $144.21M | - | -% | -32.9% | $3.99 | Compare |
|
IPHA
Innate Pharma S.A.
|
BEARISH | $132.24M | - | -% | -% | $1.41 | Compare |
|
NYXH
Nyxoah SA
|
BEARISH | $147.36M | - | -111.0% | -% | $3.38 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | CRAWFORD AMANDA TWEDE | Chief Financial Officer | Stock Award | 32,032 | $157,533 |
| 2026-01-20 | HARRIS JONATHAN | Chief Executive Officer | Sale | 2,311 | $30,806 |
| 2026-01-20 | CRAWFORD AMANDA TWEDE | Chief Financial Officer | Sale | 183 | $2,439 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning OWLT from our newsroom.